Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

43.72USD
12:03am IST
Change (% chg)

$0.05 (+0.11%)
Prev Close
$43.67
Open
$43.68
Day's High
$43.83
Day's Low
$43.47
Volume
1,840,670
Avg. Vol
6,751,675
52-wk High
$46.46
52-wk Low
$36.03

Select another date:

Thu, Jun 20 2019

Photo

GSK offers concessions to address EU concerns over Pfizer deal

BRUSSELS GlaxoSmithKline has offered concessions to address EU antitrust concerns over its planned joint venture with Pfizer's consumer health business, the European Commission said on Thursday.

GSK offers concessions to address EU concerns over Pfizer deal

BRUSSELS, June 20 GlaxoSmithKline has offered concessions to address EU antitrust concerns over its planned joint venture with Pfizer's consumer health business, the European Commission said on Thursday.

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

Pfizer to buy Array for $10.64 bln

June 17 Pfizer Inc said on Monday it had agreed to acquire Array Biopharma Inc for $10.64 billion, which will grant it access to its cancer drugs.

Novartis hopes Kisqali data will help narrow gap to blockbuster rival

ZURICH Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer's blockbuster Ibrance.

Pfizer's atopic dermatitis treatment meets goals in late-stage study

Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

UPDATE 1-Pfizer's atopic dermatitis treatment meets goals in late-stage study

May 15 Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

Pfizer's dermatitis treatment meets main goals of late-stage study

May 15 Pfizer Inc's dermatitis treatment met the main goals in a late-study, testing the drug in patients aged 12 and older with moderate to severe form of the disease, the drugmaker said on Wednesday.

BUZZ-Teva Pharma: Falls to near 1-1/2 yr low after U.S. states file price-fixing lawsuit

** Drugmaker's U.S.-listed shares fall as much as 16.4% to $12.05, touching lowest in ~1-1/2 yrs

Select another date: